← Back to patent-cliff list
Nebivolol Hydrochloride
Tier C — Watch / tradeNebivolol Hydrochloride
Johnson & Johnson Innovative Medicine
Originator
1997
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：ADRB1
Brand：Lobivon, Nebilox, Solistar, Nebilet, Bystolic
Indications (approved)：Hypertension
Regional status
US
Approved
2007-12-17
EU
Approved
1997-01-01
China
Phase III
2014-12-30
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Nebivolol Hydrochloride?
Approved indications include: Hypertension.
When does the Nebivolol Hydrochloride patent expire?
No public expiry year is available for Nebivolol Hydrochloride yet; this page updates once verified.
How do I get a quote for Nebivolol Hydrochloride intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-27